{"entity":{"id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 2 trial of Ubamatamab and REGN7075 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07154290 by Regeneron Pharmaceuticals, with 300 participants planned, started 2026-03-18 and due to reach its primary completion in 2030-06-10. Interventions recorded: Ubamatamab, Marlotamig and Sarilumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07154290","url":"https://clinicaltrials.gov/study/NCT07154290"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ubamatamab","regn7075"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07154290","phase":"2","setting":"A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Regeneron Pharmaceuticals","enrolled":300,"outcomes":[]},"route":"/trials/nct07154290/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/"},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}